IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Various
tifacogin TFP 561 V3X, J1X9 III
oral phosphate binder SBR 759 V3G II
TIFACOGIN (TFP 561) is a re com bi nant form of tis sue fac tor path way in hib i tor (TFPI), for the treat ment
of com mu nity-ac quired pneu mo nia (CAP) and sep tic shock. Phase III tri als are un der way in CAP.
Tifacogin was iso lated as part of a col lab o ra tion with Wash ing ton Uni ver sity Med i cal School, St Louis
(USA). Pfizer iso lated tifacogin in de pend ently in 1994. Un der a col lab o ra tive agree ment, Pharmacia (now
Pfizer) and Chiron (now Novartis) were to grant each other li censes to pat ents and col lab o rate as equal
part ners in all as pects of re search and de vel op ment. Chiron (now Novartis) was to have re spon si bil ity for
man u fac tur ing the prod uct, and Pfizer was to be re spon si ble for mar ket ing. Fol low ing the merger of
Pharmacia and Pfizer, Chiron (now Novartis) has ac quired all of Pfizer’s in ter est in tifacogin in re turn for
royalties paid to Pfizer on sales of the product.
Sales/An a lyst Com ment: Cowen & Co an a lysts (Au gust 2008) fore cast ini tial sales of $50 mil lion in
2010 ($150 mil lion by 2013).
SBR 759, an oral phos phate binder with po ten tial for the treat ment of hyperphosphatemia in late or
end stage re nal dis ease pa tients, was in phase II tri als in Eu rope in 2008.
Li cens ing: In 2005, Novartis ac quired rights to SBR 759 from SeBo (Ger many). Un der the terms of the
deal, Novartis will de velop, man u fac ture and com mer cial ize SBR 759 for the treat ment of chronic kid ney
dis ease pa tients or pa tients on di al y sis. These groups of pa tients have re duced phos phate ex cre tion,
which leads to hyperphosphatemia. Novartis said it has had the po ten tial to of fer di al y sis pa tients a more
po tent and con ve nient oral treat ment than cur rent ther a pies. It plans to file for approval in 2010.
Sales/An a lyst Com ment: Cowen & Co an a lysts (Au gust 2008) fore cast ini tial sales of $50 mil lion in
2011 ($100 mil lion by 2013).
© 2009 IMS Health In cor po rated or its af fil i ates Page 107